Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Thank you
Mostly I am in OBI
but it has not ski-rocketed yet
So am in here
Only a matter of time
Ross also highlighted Ondine's commercial momentum, including the deployment of Steriwave in eight new healthcare facilities and a growing international presence, now spanning 22 facilities in Canada and expanding in the UK and Spain.
The success is attributed partly to Steriwave's effectiveness in reducing the need for antibiotics, as demonstrated in a UK study, and its alignment with antimicrobial resistance efforts. Ondine plans to continue expanding in European markets, capitalize on its success in Canada, and explore potential in the United States through FDA phase three trials.
Ondine Biomedical Inc - Vancouver-based life sciences company - Announces significant commercial progress to date in 2024, ahead of management's expectations. Says Ondine's Steriwave technology is deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago. Two orthopedic surgeon group practices in the Toronto area will also shortly begin offering Steriwave to patients undergoing elective orthopedic procedures.
Current stock price: 9.64 pence, up 4.2% in London on Friday
BRIEF – Ondine Biomedical Says First Commercial Adoption Of Steriwave By NHS
07:57
March 25 (Reuters) – Ondine Biomedical Inc :
First Commercial Adoption Of Steriwave By Nhs
Source text for Eikon: ... Further company coverage:
(Reuters.Briefs@thomsonreuters.com;;)
Copyright 2024 Thomson Reuters. Click for restrictions.
The snowball is certainly gaining momentum as revenues will likely follow
First commercial adoption of Steriwave by the NHS
NHS deal gives patients access to groundbreaking
Target 60p
9.535-9.9p
Steriwave study shows 77% drop in antibi
Just my opinion
but looks likely
9.55-10.4p
Results presented at the the prestigious SPIE Photonics West conference
(https://www.londonstockexchange.com/news-article/OBI/microbiome-research-supports-use-of-steriwave/16310998)
on 30 January 2024 in San Francisco, California showed that treatment with
Ondine's Steriwave® Nasal Photodisinfection System significantly reduces
pathogens in the nose without long-term adverse effects on the nasal
microbiome. This is an important finding to allay potential concerns as to a
possible side-effect of Steriwave treatment, which has been used in over
150,000 patients with no serious adverse events reported.
5 million shares BUYS today means some thing is happening
Expect this sleeping giant to awake within weeks
Ondine Biomedical Inc - Vancouver-based life sciences company - Announces significant commercial progress to date in 2024, ahead of management's expectations. Says Ondine's Steriwave technology is deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago. Two orthopedic surgeon group practices in the Toronto area will also shortly begin offering Steriwave to patients undergoing elective orthopedic procedures.
See
Current price
32.12-32.65p